Chemotherapy and anaesthetic drugs: Too little is known

Lancet Oncology

Volumn 6, Issue 3, 2005, Pages 176-181

  Zaniboni, Alberto ^a   Prabhu, Swapna ^b   Audisio, Riccardo A ^c  

^a Oncologia Medica   (Italy)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ATRACURIUM; AZATHIOPRINE; BLEOMYCIN; CISATRACURIUM; CYCLOPHOSPHAMIDE; DESFLURANE; DIAZEPAM; DOXORUBICIN; ENFLURANE; ETOMIDATE; HALOTHANE; ISOFLURANE; KETAMINE; LIDOCAINE; LORAZEPAM; MIDAZOLAM; MIVACURIUM; NITROUS OXIDE; PANCURONIUM; PROCAINE; PROPOFOL; ROCURONIUM; SEVOFLURANE; TEMAZEPAM; THIOPENTAL; UNINDEXED DRUG; VECURONIUM;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER RESEARCH; CANCER SURGERY; CARDIOMYOPATHY; DIGESTIVE SYSTEM CANCER; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG SURVEILLANCE PROGRAM; HUMAN; IN VITRO STUDY; KIDNEY GRAFT REJECTION; LUNG CANCER; LUNG FIBROSIS; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RECTUM CANCER; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; SOFT TISSUE CANCER; SUPRAVENTRICULAR TACHYCARDIA; TESTIS CANCER;

EID: 14544307385     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)01768-7     Document Type: Note

References (32)

1. Inada T Yamanouchi Y Jomura S et al. Effect of propofol and isoflurane anaesthesia on the immune response to surgery Anaesthesia 59 2004 954-59
2. Manzullo EF Weed HG. Perioperative issues in patients with cancer Med Clin North Am 87 2003 243-56
3. Lefor AT. Perioperative management of the patient with cancer. Chest 1999; 115 (5 suppl): 165S-171S.
4. Balis FM. Pharmacokinetic drug interactions of commonly used anticancer drugs Clin Pharmacokinet 11 1986 223-35
5. Koseoglu V Chiang J Chan KW. Acquired pseudocholinesterase deficiency after high-dose cyclophosphamide Bone Marrow Transplant 24 1999 1367-68
6. Okamoto T Ogata J Minami K. Sino-atrial block during anesthesia in a patient with breast cancer being treated with the anticancer drug epirubicin Anesth Analg 97 2003 19-20
7. Klein DS Wilds PR. Pulmonary toxicity of antineoplastic agents: anaesthetic and postoperative implications Can Anaesth Soc J 30 1983 399-05
8. Comis RL. Bleomycin pulmonary toxicity: Current status and future directions Semin Oncol 192 Supp l5 1992 64-70
9. Donat SM Levy DA. Bleomycin associated pulmonary toxicity: Is perioperative oxygen restriction necessary? J Urol 160 1998 1347-52
10. Waid-Jones MI Coursin DB. Perioperative considerations for patients treated with bleomycin Chest 99 1991 993-99
11. Strickland RA Spackman TN Wedel DJ. Anesthetic management of bleomycin-treated patients Mayo Clin Proc 66 1991 548
12. al-Jafari AA Duhaiman AS Kamal MA. Inhibition of human acetylcholinesterase by cyclophosphamide Toxicology 96 1995 1-6
13. Chung F. Cancer, chemotherapy and anaesthesia Can Anaesth Soc J 29 1982 364-71
14. McLeod HL. Clinically relevant drug-drug interactions in oncology Br J Clin Pharmacol 45 1998 539-44
15. Beijnen JH Schellens JHM. Drug interactions in oncology Lancet Oncol 5 2004 489-96
16. Christensen Q Bonde L Kampmann JP. Drug interactions with intravenous and local anaesthetics Acta Anaesthesiol Scand 38 1994 15-29
17. Kvolik S Glavas-Obrovac L Sakic K et al. Anaesthetic implications of anticancer chemotherapy Eur J Anaesthesiol 20 2003 859-71
18. Gramstad L. Atracurium, vecuronium and pancuronium in end-stage renal failure. Dose-response properties and interactions with azathioprine Br J Anaesth 59 1987 995-1003
19. Kennedy KA Hait VN Lazo JS. Chemical modulation of bleomycin induced toxicity Int J Radiat Oncol Biol Phys 12 1986 1367-70
20. Zhu J Kaplan AM Goud SN. Immunologic alterations in bleomycin-treated mice: Role of pulmonary fibrosis in the modulation of immune responses Am J Respir Crit Care Med 153 1996 1924-30
21. Ingrassia TS 3rd, Ryu JH, Trastek VF, Rosenow EC 3rd. Oxygen-exacerbated bleomycin pulmonary toxicity. Mayo Clin Proc 1991; 66: 173-78.
22. Rosenow S Kooistra KL Powis G Van Dyke RA. Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane Cancer Chemother Pharmacol 16 1986 35-42
23. Van Dyke RA Powis G. Lethal effect of co-administration of halothane and cyclophosphamide in mice Anaesthesiology 59 1983 A240
24. Lee JT. Failure to detect toxicity with the concomitant use of cyclophosphamide and halothane in humans Anaesthesiology 64 1986 810-11
25. Zsigmond EK Robins G. The effect of a series of anticancer drugs on plasma cholinesterase activity Can Anaesth Soc J 19 1972 75-82
26. Chlebowski RT Block JB Cundiff D Dietrich MF. Doxorubicin cytotoxicity enhanced by local anaesthetics in a human melanoma cell line Cancer Treat Rep 66 1982 121-25
27. Huettemann E Junker T Chatzinikolaou KP et al. The influence of anthracycline therapy on cardiac function during anesthesia Anesth Analg 98 2004 941-47
28. Owczuk R Wujtewicz MA Sawicka W et al. Is prolongation of QTc interval during isoflurane anaesthesia more prominent in women pretreated with anthracyclines for breast cancer? Br J Anaesth 92 2004 658-61
29. Thorne AC Orazem JP Shah NK et al. Isoflurane versus fentanyl: hemodynamic effects in cancer patients treated with anthracyclines J Cardiothorac Vasc Anesth 7 1993 307-11
30. Frenia ML Long KS. Methotrezate and NSAID interactions Ann Pharmacother 26 1992 234-37
31. Goldhirsch A Gelber RD Tattersall MN et al. Methotrexate/nitrous-oxide toxic interaction in perioperative chemotherapy for early breast cancer Lancet 330 1987 151
32. Ermens AA Schoester M Spijkers LJ et al. Toxicity of methotrexate in rats preexposed to nitrous oxide Cancer Res 49 1989 6337-41